Last reviewed · How we verify
Total Therapy II
Total Therapy II is a Small molecule drug developed by University of Arkansas. It is currently in Phase 1 development. Also known as: vincristine, doxorubicin, dexamethasone, cyclophosphamide.
Total Therapy II is a treatment approach that combines multiple interventions, including MVX-ONCO-1, Atomoxetine, and Capecitabine, to target various conditions such as Head and Neck Squamous Cell Carcinoma, Pancreatic Cancer, and Kidney Cancer. The treatment modality of MVX-ONCO-1 is a protein-based approach.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Total Therapy II |
|---|---|
| Also known as | vincristine, doxorubicin, dexamethasone, cyclophosphamide, etoposide |
| Sponsor | University of Arkansas |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- DIARRHOEA
- STOMATITIS ALL
- NAUSEA
- NEUTROPENIA
- Hyperglycemia
- Hypocalcemia
- Peripheral sensory neuropathy
- ALOPECIA
- FATIGUE
- VOMITING
- Tumor lysis syndrome
- Alanine aminotransferase increased
Key clinical trials
- Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (PHASE2)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma (PHASE2)
- LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma (PHASE2)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Total Therapy II CI brief — competitive landscape report
- Total Therapy II updates RSS · CI watch RSS
- University of Arkansas portfolio CI
Frequently asked questions about Total Therapy II
What is Total Therapy II?
Who makes Total Therapy II?
Is Total Therapy II also known as anything else?
What development phase is Total Therapy II in?
What are the side effects of Total Therapy II?
Related
- Manufacturer: University of Arkansas — full pipeline
- Also known as: vincristine, doxorubicin, dexamethasone, cyclophosphamide, etoposide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing